Adverse event reporting in patients treated with levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society

Endocrine Practice

Volumn 16, Issue 3, 2010, Pages 357-370

  Hennessey, James V ^a   Malabanan, Alan O ^a   Haugen, Bryan R ^b   Levy, Elliot G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE SODIUM; THYROTROPIN; THYROXINE;

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGIST; AMERICAN THYROID ASSOCIATION; ANXIETY; ARTICLE; CLINICAL PRACTICE; CONFUSION; CONGENITAL HYPOTHYROIDISM; CONSTIPATION; DEPRESSION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRY SKIN; FATIGUE; GOITER; HAIR LOSS; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MENSTRUAL IRREGULARITY; NERVOUSNESS; PATIENT COMPLIANCE; PHYSICIAN; RHABDOMYOLYSIS; SIDE EFFECT; SLEEP DISORDER; THE ENDOCRINE SOCIETY; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; UNITED STATES;

DATA COLLECTION; HUMANS; SOCIETIES, MEDICAL; THYROXINE; UNITED STATES;

EID: 77956642208     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP0362.OR     Document Type: Article

References (20)

1. Hennessey JV. Precise thyroxine dosing: Clinical requirements. The Endocrinologist. 2003;13:478-487.
2. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229-1242.
3. Ain KB, Refetoff S, Fein HG, Weintraub BD. Pseudomalabsorption of levothyroxine. JAMA. 1991;266:2118-2120.
4. Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother. 2001;35:1578-1583. (Pubitemid 34027459)
5. Sherman SI, Teilens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994;96:531-535. (Pubitemid 24184438)
6. John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. Thyroid. 2007;17:763-765. (Pubitemid 350194737)
7. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. An evaluation of the adequacy of outpatient monitoring of thyroid replacement therapy. J Eval Clin Pract. 2004;10:525-530. (Pubitemid 39469036)
8. Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab. 2009;94:1342-1345.
9. Loh JA, Wartofsky L, Jonklaas J, Burman KD. The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 2009;19:269-275.
10. Hallengren B, Lantz M, Andreasson B, Grennert L. Pregnant women on thyroxine substitution are often dysregulated in early pregnancy. Thyroid. 19:391-394.
11. 1997 Docket Number 97N-0314, Prescription Drug Products; Levothyroxine Sodium Federal Register 62:43535-43538.
12. Hennessey JV. Levothyroxine dosage and the limitations of current bioequivalence standards. Nat Clin Pract Endocrinol Metab. 2006;2:474-475. (Pubitemid 44353283)
13. Blakesley VA, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 2004;14:191-200. (Pubitemid 38452191)
14. US Department of Health and Human Services, US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: www.fda.gov/cder/ob/docs/queryai.htm. Accessed November 16, 2008.
15. US Department of Health and Human Services, US Food and Drug Administration. Drugs@FDA Glossary of Terms. Available at: http://www.fda.gov/ Drugs/InformationOnDrugs/ucm079436.htm#T. Accessed November 25, 2009.
16. US Department of Health and Human Services, US Food and Drug Administration. Questions and Answers on Levothyroxine Sodium Products. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm161266.htm. Accessed December 9, 2009.
17. Burman K, Hennessey J, McDermott M, Wartofsky L, Emerson C. The FDA revises requirements for levothyroxine products. Thyroid. 2008;18:487-490. (Pubitemid 351667842)
18. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808-812.
19. IMShealth.com. IMS National Prescription Audit 2009. IMS Health Next Generation Prescription Services: Norwalk, CT.
20. Safer JD, Hennessey JV, Braverman LE. Substituting brand name levothyroxine preparations with generics would increase treatment costs. Available at: http://www.annals.org/cgi/eletters/142/11/891. Published August 1, 2005.